News headlines about Sangamo Therapeutics (NASDAQ:SGMO) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.4977926228728 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Sangamo Therapeutics (NASDAQ SGMO) opened at $17.75 on Friday. The company has a market cap of $1,479.12, a price-to-earnings ratio of -25.72 and a beta of 3.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64. Sangamo Therapeutics has a 12 month low of $3.35 and a 12 month high of $19.50.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. sell-side analysts forecast that Sangamo Therapeutics will post -0.73 EPS for the current year.
Several research firms recently weighed in on SGMO. Jefferies Group reiterated a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a report on Friday, October 13th. Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a research note on Wednesday, November 15th. BidaskClub upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, November 15th. Finally, Barclays began coverage on shares of Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target for the company. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $18.83.
In other news, VP Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock in a transaction on Friday, December 1st. The shares were sold at an average price of $16.13, for a total transaction of $268,241.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Monday, January 8th. The stock was sold at an average price of $17.11, for a total transaction of $85,550.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,433 shares of company stock valued at $979,696. Insiders own 5.50% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.